Table 7.
Studies based on data from the surveillance, epidemiology, and end results (SEER) database in an attempt to define the role of adjuvant radiotherapy in retroperitoneal sarcoma.
| Author | Inclusion | N | Inclusion criteria | Statistical methods | Significant covariates for OS/DSS | RT |
|---|---|---|---|---|---|---|
| Porter (132) | 1973–2001 | 1226 surgery 428 surgery with RT (85.5% of RT postop) | Age ≥18 | Logistic regression (use of RT) | – | Adjuvant radiotherapy use varies significantly with age, race, and geographical location |
| Nathan (133) | 1988–2005 | 1365 | Curative intent surgery | Cox regression | Age, sex, grade, histology | Unadjusted Cox analysis: HR for OS 0.78–1.15 |
| Zhou (134) | 1988–2005 | 1574 | Age ≥18 | Cox regression Stratified for AJCC stage | Surgery, age, sex, stage | Stage I: HR for OS 0.25–0.96 Stage II/III: HR for OS 0.58–1.06 |
| Tseng (135) | 1988–2004 | 1130 surgery 373 surgery with RT (80.4% of RT postop) | Age ≥18 Patients underwent surgery | Cox regression | Age, sex, histology, grade Complete resection | Cox regression: HR for OS 0.78–1.09 overall OS benefit in MFH (P = 0.002) and dedifferentiated liposarcoma (P = 0.08) in univariate analysis |
| Choi (136) | 1988–2006 | 558 surgery 204 surgery with RT (80% of RT postop) | Age ≥20, single malignancy Curative intent surgery | Cox regression; propensity score matching | Age, sex, grade, stage | Cox regression: HR for DSS 0.87–1.56 After PS matching: no difference in DSS (P = 0.35) or OS (P = 0.1) |
OS, overall survival; DSS, disease-specific survival; HR, hazard ratio; MFH, malignant fibrous hstiocytoma; PS, propensity score.